Lenvatinib for the treatment of renal cell carcinoma

Giandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, Michele Aieta, Daniele Generali, Maria Grazia Rodriquenz, Anna Maria Mileo, Marco Imperatori, Anna Ianza, Raffaele Conca, Navid Sobhani

Research output: Contribution to journalReview articlepeer-review


INTRODUCTION: Renal cell carcinoma (RCC) accounts for 2-3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC. Areas covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma. Expert opinion: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy.

Original languageEnglish
Pages (from-to)507-512
Number of pages6
JournalExpert Opinion on Investigational Drugs
Issue number5
Publication statusPublished - May 2018


  • Angiogenesis Inhibitors/administration & dosage
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Carcinoma, Renal Cell/drug therapy
  • Everolimus/administration & dosage
  • Humans
  • Kidney Neoplasms/drug therapy
  • Phenylurea Compounds/administration & dosage
  • Protein Kinase Inhibitors/administration & dosage
  • Quinolines/administration & dosage
  • Vascular Endothelial Growth Factor A/antagonists & inhibitors


Dive into the research topics of 'Lenvatinib for the treatment of renal cell carcinoma'. Together they form a unique fingerprint.

Cite this